|
|
Blood, 15 February 2005, Vol. 105, No. 4, pp. 1686-1693.
Prepublished online as a Blood First Edition Paper on October 21, 2004; DOI 10.1182/blood-2004-07-2730.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization
Margit Schraders,
Rolph Pfundt,
Huub M. P. Straatman,
Irene M. Janssen,
Ad Geurts van Kessel,
Eric F. P. M. Schoenmakers,
Johan H. J. M. van Krieken, and
Patricia J. T. A. Groenen
From the Departments of Pathology, Human Genetics, and Epidemiology and Biostatistics, University Medical Centre Nijmegen, Nijmegen, The Netherlands.
Mantle cell lymphoma (MCL) is an aggressive, highly proliferative B-cell non-Hodgkin lymphoma, characterized by the specific t(11;14)(q13;q32) translocation. It is well established that this translocation alone is not sufficient to promote MCL development, but that additional genetic changes are essential for malignant transformation. We have identified such additional tumorigenic triggers in MCL tumors, by applying genome-wide array-based comparative genomic hybridization with an 800-kilobase (kb) resolution. This strategy, combined with a newly developed statistical approach, enabled us to confirm previously reported genomic alterations such as loss of 1p, 6q, 11q, 13q and gain of 3q and 8q, but it also facilitated the detection of novel recurrent genomic imbalances, such as gain of 4p12-13 and loss of 20p12.1-12.3, 20q12-13.2, 22q12.1-12.3, and 22q13.31-13.32. Genomic hotspot detection allowed for the identification of small genomic intervals that are frequently affected (57%-93%), resulting in interesting positional candidate genes such as KITLG, GPC5, and ING1. Finally, by assessing multiple biopsies from the same patient, we show that seemingly stable genomes do show subtle genomic changes over time. The follow-up of multiple biopsies of patients with MCL by high-resolution genomic profiling is expected to provide us with new clues regarding the relation between clinical outcome and in vivo cytogenetic evolution. (Blood. 2005;105:1686-1693)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Sander, L. Bullinger, E. Leupolt, A. Benner, D. Kienle, T. Katzenberger, J. Kalla, G. Ott, H. K. Muller-Hermelink, T. F.E. Barth, et al.
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations
Haematologica,
May 1, 2008;
93(5):
680 - 687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kawamata, J. Chen, and H. P. Koeffler
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Blood,
October 1, 2007;
110(7):
2667 - 2673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al.
Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors
J. Clin. Oncol.,
July 1, 2007;
25(19):
2770 - 2777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ripperger, N. von Neuhoff, K. Kamphues, M. Emura, U. Lehmann, M. Tauscher, M. Schraders, P. Groenen, B. Skawran, C. Rudolph, et al.
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle cell lymphomas
Haematologica,
April 1, 2007;
92(4):
460 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Salaverria, A. Zettl, S. Bea, V. Moreno, J. Valls, E. Hartmann, G. Ott, G. Wright, A. Lopez-Guillermo, W. C. Chan, et al.
Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature
J. Clin. Oncol.,
April 1, 2007;
25(10):
1216 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Wlodarska, C. Matthews, E. Veyt, H. Pospisilova, M. A. Catherwood, T. S. Poulsen, V. Vanhentenrijk, R. Ibbotson, P. Vandenberghe, T.C.M. C. Morris, et al.
Telomeric IGH Losses Detectable by Fluorescence in Situ Hybridization in Chronic Lymphocytic Leukemia Reflect Somatic VH Recombination Events
J. Mol. Diagn.,
February 1, 2007;
9(1):
47 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rouveirol, N. Stransky, Ph. Hupe, Ph. L. Rosa, E. Viara, E. Barillot, and F. Radvanyi
Computation of recurrent minimal genomic alterations from array-CGH data
Bioinformatics,
April 1, 2006;
22(7):
849 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Greiner, C. Dasgupta, V. V. Ho, D. D. Weisenburger, L. M. Smith, J. C. Lynch, J. M. Vose, K. Fu, J. O. Armitage, R. M. Braziel, et al.
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
PNAS,
February 14, 2006;
103(7):
2352 - 2357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-M. Kim, S.-H. Yim, J.-S. Lee, M.-S. Kwon, J.-W. Ryu, H.-M. Kang, H. Fiegler, N. P. Carter, and Y.-J. Chung
Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers
Clin. Cancer Res.,
December 1, 2005;
11(23):
8235 - 8242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Witzig
Current Treatment Approaches for Mantle-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6409 - 6414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Rubio-Moscardo, J. Climent, R. Siebert, M. A. Piris, J. I. Martin-Subero, I. Nielander, J. Garcia-Conde, M. J. S. Dyer, M. J. Terol, D. Pinkel, et al.
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
Blood,
June 1, 2005;
105(11):
4445 - 4454.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
